Use of Ketamine in Clinical Practice: A Time for Optimism and Caution

Increasing evidence, primarily from small studies, supports the idea that the dissociative anesthetic ketamine has rapid antidepressant effects in patients with treatment-refractory major depression. The beneficial effects of ketamine are observed within hours of administration and can last approxim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA psychiatry (Chicago, Ill.) Ill.), 2017-04, Vol.74 (4), p.405-406
Hauptverfasser:	Zorumski, Charles F, Conway, Charles R
Format:	Artikel
Sprache:	eng
Schlagworte:	Anesthesia Antidepressants Ketamine Mental depression Optimism Prescription drugs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	406
container_issue	4
container_start_page	405
container_title	JAMA psychiatry (Chicago, Ill.)
container_volume	74
creator	Zorumski, Charles F Conway, Charles R
description	Increasing evidence, primarily from small studies, supports the idea that the dissociative anesthetic ketamine has rapid antidepressant effects in patients with treatment-refractory major depression. The beneficial effects of ketamine are observed within hours of administration and can last approximately 1 week. Given that up to one-third of patients with major depression fail current treatments, there is a clear need for novel and more effective treatments. Results to date have led to increasing off-label use of ketamine in clinical practices, with little guidance about clinical administration. In this issue of the JAMA Psychiatry, Sanacora and colleagues provide a much-needed consensus statement to help guide clinical use of ketamine.
doi_str_mv	10.1001/jamapsychiatry.2017.0078
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1873723372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2605197</ama_id><sourcerecordid>1873723372</sourcerecordid><originalsourceid>FETCH-LOGICAL-a307t-d359eefa4db7dc6e8404d9cd4d755e438f8c890281cf2df65e9b188952bf2f513</originalsourceid><addsrcrecordid>eNpdkFtLwzAYhoMoTub-gBcS8Mabzpzapt6NMg84mBcbeFfSHDCjJ5P2Yv_elM2JBkICeb43Lw8AEKM5Rgg_7EQtOr-Xn1b0bj8nCKdzhFJ-Bq4ITniUEMrPT3fyMQEz73coLI4Qo_wSTAgnLEMJuwLLrdewNfBN96K2jYa2gXllGytFBd-dkL2V-hEu4MbWGprWwXXX29r6GopGwVwMvW2ba3BhROX17HhOwfZpuclfotX6-TVfrCJBUdpHisaZ1kYwVaZKJpozxFQmFVNpHOtQzXDJM0Q4loYok8Q6KzHnWUxKQ0yM6RTcH3I7134N2vdFaCJ1VYlGt4MvME9pSui4p-DuH7prB9eEdoEKmYxSygLFD5R0rfdOm6JzthZuX2BUjLaLv7aL0XYx2g6jt8cPhrLW6jT44zYANwcgJPy-JijGWUq_AbmJhjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1888943334</pqid></control><display><type>article</type><title>Use of Ketamine in Clinical Practice: A Time for Optimism and Caution</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Zorumski, Charles F ; Conway, Charles R</creator><creatorcontrib>Zorumski, Charles F ; Conway, Charles R</creatorcontrib><description>Increasing evidence, primarily from small studies, supports the idea that the dissociative anesthetic ketamine has rapid antidepressant effects in patients with treatment-refractory major depression. The beneficial effects of ketamine are observed within hours of administration and can last approximately 1 week. Given that up to one-third of patients with major depression fail current treatments, there is a clear need for novel and more effective treatments. Results to date have led to increasing off-label use of ketamine in clinical practices, with little guidance about clinical administration. In this issue of the JAMA Psychiatry, Sanacora and colleagues provide a much-needed consensus statement to help guide clinical use of ketamine.</description><identifier>ISSN: 2168-622X</identifier><identifier>EISSN: 2168-6238</identifier><identifier>DOI: 10.1001/jamapsychiatry.2017.0078</identifier><identifier>PMID: 28249064</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Anesthesia ; Antidepressants ; Ketamine ; Mental depression ; Optimism ; Prescription drugs</subject><ispartof>JAMA psychiatry (Chicago, Ill.), 2017-04, Vol.74 (4), p.405-406</ispartof><rights>Copyright American Medical Association Apr 1, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/articlepdf/10.1001/jamapsychiatry.2017.0078$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2017.0078$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3338,27923,27924,76260,76263</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28249064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zorumski, Charles F</creatorcontrib><creatorcontrib>Conway, Charles R</creatorcontrib><title>Use of Ketamine in Clinical Practice: A Time for Optimism and Caution</title><title>JAMA psychiatry (Chicago, Ill.)</title><addtitle>JAMA Psychiatry</addtitle><description>Increasing evidence, primarily from small studies, supports the idea that the dissociative anesthetic ketamine has rapid antidepressant effects in patients with treatment-refractory major depression. The beneficial effects of ketamine are observed within hours of administration and can last approximately 1 week. Given that up to one-third of patients with major depression fail current treatments, there is a clear need for novel and more effective treatments. Results to date have led to increasing off-label use of ketamine in clinical practices, with little guidance about clinical administration. In this issue of the JAMA Psychiatry, Sanacora and colleagues provide a much-needed consensus statement to help guide clinical use of ketamine.</description><subject>Anesthesia</subject><subject>Antidepressants</subject><subject>Ketamine</subject><subject>Mental depression</subject><subject>Optimism</subject><subject>Prescription drugs</subject><issn>2168-622X</issn><issn>2168-6238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkFtLwzAYhoMoTub-gBcS8Mabzpzapt6NMg84mBcbeFfSHDCjJ5P2Yv_elM2JBkICeb43Lw8AEKM5Rgg_7EQtOr-Xn1b0bj8nCKdzhFJ-Bq4ITniUEMrPT3fyMQEz73coLI4Qo_wSTAgnLEMJuwLLrdewNfBN96K2jYa2gXllGytFBd-dkL2V-hEu4MbWGprWwXXX29r6GopGwVwMvW2ba3BhROX17HhOwfZpuclfotX6-TVfrCJBUdpHisaZ1kYwVaZKJpozxFQmFVNpHOtQzXDJM0Q4loYok8Q6KzHnWUxKQ0yM6RTcH3I7134N2vdFaCJ1VYlGt4MvME9pSui4p-DuH7prB9eEdoEKmYxSygLFD5R0rfdOm6JzthZuX2BUjLaLv7aL0XYx2g6jt8cPhrLW6jT44zYANwcgJPy-JijGWUq_AbmJhjQ</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Zorumski, Charles F</creator><creator>Conway, Charles R</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Use of Ketamine in Clinical Practice: A Time for Optimism and Caution</title><author>Zorumski, Charles F ; Conway, Charles R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a307t-d359eefa4db7dc6e8404d9cd4d755e438f8c890281cf2df65e9b188952bf2f513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anesthesia</topic><topic>Antidepressants</topic><topic>Ketamine</topic><topic>Mental depression</topic><topic>Optimism</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zorumski, Charles F</creatorcontrib><creatorcontrib>Conway, Charles R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zorumski, Charles F</au><au>Conway, Charles R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Ketamine in Clinical Practice: A Time for Optimism and Caution</atitle><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle><addtitle>JAMA Psychiatry</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>74</volume><issue>4</issue><spage>405</spage><epage>406</epage><pages>405-406</pages><issn>2168-622X</issn><eissn>2168-6238</eissn><abstract>Increasing evidence, primarily from small studies, supports the idea that the dissociative anesthetic ketamine has rapid antidepressant effects in patients with treatment-refractory major depression. The beneficial effects of ketamine are observed within hours of administration and can last approximately 1 week. Given that up to one-third of patients with major depression fail current treatments, there is a clear need for novel and more effective treatments. Results to date have led to increasing off-label use of ketamine in clinical practices, with little guidance about clinical administration. In this issue of the JAMA Psychiatry, Sanacora and colleagues provide a much-needed consensus statement to help guide clinical use of ketamine.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>28249064</pmid><doi>10.1001/jamapsychiatry.2017.0078</doi><tpages>2</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 2168-622X
ispartof	JAMA psychiatry (Chicago, Ill.), 2017-04, Vol.74 (4), p.405-406
issn	2168-622X 2168-6238
language	eng
recordid	cdi_proquest_miscellaneous_1873723372
source	MEDLINE; American Medical Association Journals
subjects	Anesthesia Antidepressants Ketamine Mental depression Optimism Prescription drugs
title	Use of Ketamine in Clinical Practice: A Time for Optimism and Caution
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A02%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Ketamine%20in%20Clinical%20Practice:%20A%20Time%20for%20Optimism%20and%20Caution&rft.jtitle=JAMA%20psychiatry%20(Chicago,%20Ill.)&rft.au=Zorumski,%20Charles%20F&rft.date=2017-04-01&rft.volume=74&rft.issue=4&rft.spage=405&rft.epage=406&rft.pages=405-406&rft.issn=2168-622X&rft.eissn=2168-6238&rft_id=info:doi/10.1001/jamapsychiatry.2017.0078&rft_dat=%3Cproquest_cross%3E1873723372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1888943334&rft_id=info:pmid/28249064&rft_ama_id=2605197&rfr_iscdi=true